Center for Astrobiology, CSIC-INTA, Torrejon de Ardoz, Spain.
Exp Neurol. 2010 Sep;225(1):29-33. doi: 10.1016/j.expneurol.2009.11.017. Epub 2009 Dec 4.
Oligodendrocyte precursor cells (OPCs) become myelin-forming after their differentiation into post-mitotic oligodendrocytes. OPCs are extremely efficient at myelin repair and contribute to remyelination. However, remyelination fails in multiple sclerosis (MS), which suggest that the OPCs are ineffective in this disorder. We have studied previously the expression of heat shock protein 90 (HSP90) in OPCs and have reported autoantibodies against HSP90 in MS patients, which recognize the antigen on the OPC surface. The present study investigated a protective effect of HSP90 inhibitors observed in cultured OPCs. Radicicol and 17-allylamino-17-demethoxygeldanamycin (17-AAG) at non-cytotoxic doses targeted cell-surface HSP90 in OPCs. Thus, 0.01 nM 17-AAG or 10 nM radicicol competed with the anti-HSP90 antibodies for binding to cell-surface HSP90. These low doses of HSP90 inhibitors prevented HSP90-antibody-induced OPC death and protected the oligodendrocyte population against antibody attack. Adult oligodendrocytes were protected by these low doses of HSP90 inhibitors in a similar fashion to perinatal cells. The present results show that, despite OPCs being very sensitive to HSP90 inhibitors, low and non-cytotoxic doses of 17-AAG and radicicol protect oligodendrocytes from anti-HSP90 antibody attack. They may have therapeutic potential for MS patients that have anti-HSP90 autoantibodies and provide a novel strategy for therapeutic intervention with HSP90 inhibitors.
少突胶质前体细胞 (OPC) 在分化为有丝分裂后少突胶质细胞后成为髓鞘形成细胞。OPC 对髓鞘修复非常有效,并有助于髓鞘再生。然而,多发性硬化症 (MS) 中的髓鞘再生失败,这表明 OPC 在这种疾病中无效。我们之前研究了热休克蛋白 90 (HSP90) 在 OPC 中的表达,并报道了 MS 患者中针对 HSP90 的自身抗体,这些抗体识别 OPC 表面的抗原。本研究调查了 HSP90 抑制剂在培养的 OPC 中观察到的保护作用。利迪哲和 17-烯丙基-17-脱甲氧基格尔德霉素 (17-AAG) 在非细胞毒性剂量下靶向 OPC 细胞表面的 HSP90。因此,0.01 nM 17-AAG 或 10 nM 利迪哲与抗 HSP90 抗体竞争与细胞表面 HSP90 结合。这些低剂量的 HSP90 抑制剂可防止 HSP90 抗体诱导的 OPC 死亡,并保护少突胶质细胞免受抗体攻击。这些低剂量的 HSP90 抑制剂以类似的方式保护成年少突胶质细胞,不受 HSP90 抑制剂的影响。目前的结果表明,尽管 OPC 对 HSP90 抑制剂非常敏感,但低剂量和非细胞毒性的 17-AAG 和利迪哲可保护少突胶质细胞免受抗 HSP90 抗体的攻击。它们可能对具有抗 HSP90 自身抗体的 MS 患者具有治疗潜力,并为 HSP90 抑制剂的治疗干预提供了一种新策略。